Does TALAZOPARIB Cause Myelosuppression? 16 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Myelosuppression have been filed in association with TALAZOPARIB (Talzenna). This represents 1.1% of all adverse event reports for TALAZOPARIB.
16
Reports of Myelosuppression with TALAZOPARIB
1.1%
of all TALAZOPARIB reports
2
Deaths
3
Hospitalizations
How Dangerous Is Myelosuppression From TALAZOPARIB?
Of the 16 reports, 2 (12.5%) resulted in death, 3 (18.8%) required hospitalization.
Is Myelosuppression Listed in the Official Label?
Yes, Myelosuppression is listed as a known adverse reaction in the official FDA drug label for TALAZOPARIB.
What Other Side Effects Does TALAZOPARIB Cause?
Anaemia (219)
Neoplasm progression (169)
Death (142)
Off label use (78)
Thrombocytopenia (78)
Fatigue (77)
Platelet count decreased (68)
Haemoglobin decreased (65)
Febrile neutropenia (60)
Pancytopenia (60)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which TALAZOPARIB Alternatives Have Lower Myelosuppression Risk?
TALAZOPARIB vs TALC
TALAZOPARIB vs TALIGLUCERASE ALFA
TALAZOPARIB vs TALIMOGENE LAHERPAREPVEC
TALAZOPARIB vs TALQUETAMAB
TALAZOPARIB vs TALQUETAMAB-TGVS